Article
Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Biochemical and biophysical research communications - 22 Apr 2016
Kobayashi Isao, Takahashi Fumiyuki, Nurwidya Fariz, Nara Takeshi, Hashimoto Muneaki, Murakami Akiko, Yagishita Shigehiro, Tajima Ken, Hidayat Moulid, Shimada Naoko, Suina Kentaro, Yoshioka Yasuko, Sasaki Shinichi, Moriyama Mariko, Moriyama Hiroyuki, Takahashi Kazuhisa
Abstract excerpt
Several recent studies have suggested that cancer stem cells (CSCs) are involved in resistance to gefitinib in non-small cell lung cancer (NSCLC). Oct4, a member of the POU-domain transcription factor family, has been shown to be involved in CSC properties of various cancers. We previously reported that Oct4 and the putative lung CSC marker CD133 were highly expressed in gefitinib-resistant persisters (GRPs) in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
